Imminent final results of Phase 1 study to be released around the end of this month which will assist further partnering discussions or possibly fully licensing it out . Phase 1 is the least risky phase and they seem very confident results are going to please. Great to see doses used in Phase 1 are similar to what could be used in Phase 11 and still have a very good safely profile. This bodes well for the future as Phase 11 is much more riskier for everyone involved. Great Risk vs Reward trading around $10 to $ 12 million market cap with high impact news to come in the near term.
